BlueCrest Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlueCrest Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,715	Closed	-$652K	–	250
2020 Q1	$652K	Buy	7,715 +2,000	+35%	+$172K	0.04%	137
2019 Q4	$483K	Sell	5,715 -600	-10%	-$45.3K	0.03%	210
2019 Q3	$426K	Buy	6,315 +2,500	+66%	+$193K	0.03%	293
2019 Q2	$327K	Buy	+3,815	New	+$326K	0.02%	266
2018 Q4	–	Sell	-2,684	Closed	-$260K	–	897
2018 Q3	$260K	Buy	2,684 +454	+20%	+$45.3K	0.01%	1113
2018 Q2	$210K	Buy	+2,230	New	+$195K	0.01%	1290
2017 Q4	–	Sell	-5,347	Closed	-$498K	–	846
2017 Q3	$498K	Sell	5,347 -3,203	-37%	-$283K	0.02%	521
2017 Q2	$777K	Hold	8,550	–	–	0.03%	509
2017 Q1	$751K	Hold	8,550	–	–	0.04%	364
2016 Q4	$708K	Sell	8,550 -7,154	-46%	-$615K	0.04%	421
2016 Q3	$1.45M	Buy	15,704 +4,604	+41%	+$434K	0.05%	325
2016 Q2	$864K	Buy	+11,100	New	+$944K	0.04%	390
2016 Q1	–	Sell	-2,228	Closed	-$233K	–	791
2015 Q4	$233K	Buy	+2,228	New	+$233K	0.01%	801
2015 Q3	–	Sell	-17,400	Closed	-$2.38M	–	872
2015 Q2	$2.38M	Buy	+17,400	New	+$2.16M	0.07%	307
2014 Q4	–	Sell	-37,400	Closed	-$2.7M	–	559
2014 Q3	$2.7M	Buy	+37,400	New	+$2.46M	0.1%	200

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlueCrest Capital Management's BMRN Position: Q2 2020 in Review

BlueCrest Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 7,715 shares — an estimated $652K sold.

BlueCrest Capital Management first reported a position in BMRN in Q3 2014 and held it in 15 quarters. The position peaked at $2.7M in Q3 2014. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

BlueCrest Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
BlueCrest Capital Management sold 7,715 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $652K.
BlueCrest Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 15 quarters.
BlueCrest Capital Management's BioMarin Pharmaceuticals position peaked at $2.7M in Q3 2014.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on BlueCrest Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.